Intravenous immunoglobulin for recurrent Clostridium difficile diarrhoea
نویسندگان
چکیده
منابع مشابه
Descriptive study of intravenous immunoglobulin for the treatment of recurrent Clostridium difficile diarrhoea.
OBJECTIVES Clostridium difficile diarrhoea (CDD) cases treated with intravenous immunoglobulin during a 2 year period were reviewed to determine disease severity and response to treatment. PATIENTS AND METHODS Of 580 CD cytotoxin-positive patients, five received intravenous immunoglobulin because of protracted and/or recurrent CDD (median duration 50 days, range 45-64); two had biopsy- proven...
متن کاملIntravenous immunoglobulin for resistant Clostridium difficile infection.
Clostridium difficile (CD)-associated diarrhoea and colitis may relapse in up to 20% of treated patients. We present a patient who failed to respond over a 6-month period to treatment either singly or in combination with metronidazole, vancomycin, rifampicin, cholestyramine and probiotics. Her diarrhoea rapidly resolved after a 3-day course of intravenous immunoglobulin. This treatment may comp...
متن کاملIntravenous immunoglobulin therapy for severe Clostridium difficile colitis.
BACKGROUND Many individuals have serum antibodies against Clostridium difficile toxins. Those with an impaired antitoxin response may be susceptible to recurrent, prolonged, or severe C difficile diarrhoea and colitis. AIMS To examine whether treatment with intravenous immunoglobulin might be effective in patients with severe pseudomembranous colitis unresponsive to standard antimicrobial the...
متن کاملIntravenous Immunoglobulin in the Treatment of Severe Clostridium Difficile Colitis
Intravenous immunoglobulin (IVIG) has been utilized in patients with recurrent and refractory Clostridium difficile colitis. It is increasingly being used in patients with initial clinical presentation of severe colitis. Herein, we report a case of severe C. Difficile colitis successfully treated with IVIG with a review of the medical literature to identify the optimal timing and clinical chara...
متن کاملFidaxomicin for Clostridium difficile-Associated Diarrhoea
BACKGROUND Fidaxomicin is a macrocyclic antibiotic approved in 2011 by the US Food and Drug Administration for treatment of Clostridium difficile-associated diarrhoea (CDAD). OBJECTIVE Herein, we present an epidemiological method to estimate, on a case mix basis, and from the perspective of the US health system, the warranted (justifiable) price per day for fidaxomicin, as a percent of the wh...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
ژورنال
عنوان ژورنال: Gut
سال: 2002
ISSN: 0017-5749
DOI: 10.1136/gut.51.3.456